With our transformative microdosing technology, we are developing a treatment for progressive myopia. This condition often leads to high myopia which can increase the risk of cataract, glaucoma, retinal detachment, and myopic macular degeneration, and cause irreversible vision loss1,2,3,4,5,6. Eyenovia is a rapidly emerging clinical stage, ophthalmic biopharmaceutical company that is transforming modern eyecare primarily in areas of high unmet need including progressive myopia, presbyopia, and mydriatics. We believe our technology enables these first-in-class microdosed therapies to streamline the overall patient experience as they are designed to reduce ocular and systemic toxicity, improve the risk-benefit profile of drugs and lower the risk of drug contamination.
1. Vongphanit, J., Mitchell, P., & Wang, J. J. (2002). Prevalence and progression of myopic retinopathy in an older population. Ophthalmology, 109(4), 704-711.
2. Ogawa, A., & Tanaka, M. (1988). The relationship between refractive errors and retinal detachment–analysis of 1,166 retinal detachment cases. Japanese journal of ophthalmology, 32(3), 310-315.
3. Lim, R., Mitchell, P., & Cumming, R. G. (1999). Refractive associations with cataract: the blue mountains eye study. Investigative ophthalmology & visual science, 40(12), 3021-3026.
4. Mitchell, P., Houriha4. n, F., Sandbach, J., & Wang, J. J. (1999). The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology, 106(10), 2010-2015.
5. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641.
6. Chia, Audrey, et al. “Five-Year Clinical Trial on Atropine for the Treatment of Myopia” Ophthalmology, vol. 123, no. 2, 2016, pp. 391–399., doi:10.1016/j.ophtha.2015.07.004.